In human ventricular trabeculae, sequential and cumulative application of Tolterodine increased AP repolarization duration relative to the vehicle control period, predominantly prolonging phase 3 without notably affecting phase 2. Tolterodine had negligible effects on AP amplitude up to the highest tested concentration, 1 μM, compared with the vehicle control period. In acute parasagittal slices from the rostral pole of the gerbil AVCN, Tolterodine washin slightly decreased membrane resistance relative to control, but the difference was not statistically significant. [1,2]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Tolterodine and ventricular action potential repolarization
Cell-based study · human ventricular trabeculae [1]
In human ventricular trabeculae, sequential and cumulative application of Tolterodine at 0.1 μM and 1 μM increased action potential repolarization duration compared with the vehicle control period.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.1 and 1 μM
- Exposure duration
- Each concentration was applied for 31 min
- Method
- applied sequentially and cumulatively
- Vehicle
- Tyrode with 0.1% DMSO
- Co-treatment
- Other interventions in this design: Stimulation 1 Hz. Compound effect isolated by the comparison: vehicle control period.
Methods and source locations
Compound reported in the paper: Tolterodine
The paper names Tolterodine without stating the salt or form; not verified as the tartrate form supplied as A10937. No dose conversion or lot validation.
Methods > Recording of action potentials in human ventricular trabeculae (S33, S34); Methods > Data analysis (S38); Results > Effect of tolterodine and terodiline on AP in human ventricular trabeculae (S51, S53); Figure 2 legend (S91, S92); Figure 5 legend (S101)
duration of AP repolarization: duration of AP repolarization; comparator: vehicle control solution (Tyrode with 0.1% DMSO) — Results > Effect of tolterodine and terodiline on AP in human ventricular trabeculae (S53)
Tolterodine and ventricular action potential amplitude
Cell-based study · human ventricular trabeculae [1]
In human ventricular trabeculae, sequential and cumulative application of Tolterodine up to 1 μM had negligible effects on action potential amplitude compared with the vehicle control period.
Literature-Reported Treatment Conditions
- Treatment concentration
- up to the highest testing concentration, 1 μM
- Exposure duration
- Each concentration was applied for 31 min
- Method
- applied sequentially and cumulatively
- Vehicle
- Tyrode with 0.1% DMSO
- Co-treatment
- Other interventions in this design: Stimulation 1 Hz. Compound effect isolated by the comparison: vehicle control period.
Methods and source locations
Compound reported in the paper: Tolterodine
The paper names Tolterodine without stating the salt or form; not verified as the tartrate form supplied as A10937. No dose conversion or lot validation.
Methods > Recording of action potentials in human ventricular trabeculae (S33, S34); Methods > Data analysis (S38); Results > Effect of tolterodine and terodiline on AP in human ventricular trabeculae (S51, S54); Figure 2 legend (S91, S92); Figure 5 legend (S101)
amplitude of AP: amplitude of AP; comparator: vehicle control solution (Tyrode with 0.1% DMSO) — Results > Effect of tolterodine and terodiline on AP in human ventricular trabeculae (S54)
Tolterodine and membrane resistance in gerbil AVCN slices
Cell-based study · acute parasagittal slices were performed at the rostral pole of the gerbil AVCN (P14–P25) [2]
In acute parasagittal slices from the rostral pole of the gerbil AVCN, Tolterodine was administered by washin at 100 nm. Membrane resistance decreased slightly relative to control, but the difference was not statistically significant.
Literature-Reported Treatment Conditions
- Exposure duration
- during (Tol, 4-14min)
- Method
- washin
- Co-treatment
- Other interventions in this design: strychnine 1 µm; gabazine 10 µm; CGP-55845 2 µm. Compound effect isolated by the comparison: control, 69 ± 9 MΩ; tolterodine, 62 ± 14 MΩ.
- Reported limits
- Not stated in the sentences used: vehicle. Concentration removed by unit check.
Methods and source locations
Compound reported in the paper: Tolterodine
The paper names Tolterodine without stating the salt or form; not verified as the tartrate form supplied as A10937. No dose conversion or lot validation.
Materials and Methods > Electrophysiology (S12, S14, S15); Results (S106); Results > Muscarinic acetylcholine receptors mediate a long-lasting RMP modulation (S162, S163, S166, S167); Figure 4. legend (S308, S310, S313, S314)
membrane resistance: membrane resistance; comparator: control, 69 ± 9 MΩ — Materials and Methods > Electrophysiology (S15); Results > Muscarinic acetylcholine receptors mediate a long-lasting RMP modulation (S162, S163, S167); Figure 4. legend (S308, S310, S313, S314)